Altimmune (NASDAQ:ALT) First Half 2024 Results Key financial results Profit and sales growth All figures shown in the graph above refer to the last 12 months (TTM) Altimmune sales exceed expectations, EPS falls short of expectations Sales exceeded analysts’ estimates. Earnings per share (EPS) missed analysts’ estimates by 1.4%. An average sales growth of 72% […]